Loading...
•
Mar 31, 2023
Tvardi Therapeutics Q1 2023 Earnings Report
Cara Therapeutics reported financial results for Q1 2023, marked by revenue generation from KORSUVA injection and Kapruvia, as well as progress in late-stage oral difelikefalin clinical programs.
Key Takeaways
Cara Therapeutics reported Q1 2023 financial results, featuring $6.2 million in total revenue, including $2.8 million from KORSUVA injection sales. The company's net loss was $26.7 million, or $(0.49) per share. Vial orders for KORSUVA injection more than doubled quarter-over-quarter, indicating increased demand. The company expects its cash to fund operations into the second half of 2024.
Total revenue for Q1 2023 was $6.2 million, including $2.8 million from collaborative revenue related to KORSUVA injection.
KORSUVA injection net sales were $5.7 million, with vial orders more than doubling quarter-over-quarter.
Kapruvia generated $1.2 million in net sales and $125,000 in royalty revenue in Europe.
Net loss for Q1 2023 was $26.7 million, or $(0.49) per share.
Forward Guidance
Cara Therapeutics expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities, including collaborative revenue from its share of the profit from KORSUVA injection, will be sufficient to fund its currently anticipated operating plan into the second half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...